Keplat (Ketoprofen)

Ketoprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for prostaglandin production. Lower prostaglandin levels diminish inflammation, pain signaling, and fever, providing therapeutic relief at the site of injury or disease.

The specific dose and duration of Keplat therapy are determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and individual response. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety of ketoprofen in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Keplat product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Keplat delivers ketoprofen via a transdermal patch, offering steady systemic exposure and avoiding first‑pass metabolism, which can be advantageous over oral NSAIDs that may cause gastrointestinal irritation. Compared with other topical NSAIDs, ketoprofen provides a potent anti‑inflammatory effect suitable for moderate pain conditions.

Keplat patches should be stored at room temperature, preferably below 25 °C, in their original packaging. They must be kept away from moisture, direct sunlight and excessive heat to maintain drug stability and patch adhesion.

The patch is applied to clean, dry, hair‑free skin on a suitable area such as the upper arm or back. Press firmly for several seconds to ensure adhesion, and leave in place for the prescribed duration, typically up to 24 hours, before removal and disposal.

Serious risks include severe allergic reactions (anaphylaxis), gastrointestinal bleeding or ulceration, renal impairment, hepatotoxicity, and cardiovascular events such as myocardial infarction or stroke. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, vomiting blood, swelling of the face or difficulty breathing.

Keplat is contraindicated in individuals with known hypersensitivity to ketoprofen or any NSAID, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and patients who have experienced a recent myocardial infarction or uncontrolled heart failure.